3 Best Crypto Stocks with 120%+ Upside, According to Analysts
Using TipRanks’ Stock Comparison Tool, we identified three crypto-related stocks with a “Strong Buy” consensus rating and more than 120% upside potential over the next 12 months.
HIVE Digital (HIVE) offers Bitcoin mining exposure, Bit Digital (BTBT) focuses on Ethereum staking, while Bitdeer Technologies (BTDR) is expanding into AI and high-performance computing (HPC) infrastructure. Together, these companies offer different ways to participate in the industry’s growth, although all three stocks can be highly volatile.
Bit Digital – Bit Digital focuses on buying and staking Ethereum (ETH-USD) to earn rewards. It also provides AI computing and data center infrastructure through its subsidiary, WhiteFiber. Staking means using digital coins to help run and secure a blockchain network, earning rewards in return.
Promotion
70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Over the last three months, all four Wall Street analysts covering BTBT stock have rated it a Strong Buy. Their 12-month average Bit Digital price target indicates an upside of more than 212%.
HIVE Digital – HIVE Digital operates renewable energy-powered data centers primarily focused on Bitcoin mining. The company is also expanding its GPU infrastructure business to support AI and cloud-computing workloads, providing exposure to both the cryptocurrency and AI infrastructure markets.
In the last three months, five Wall Street analysts covering HIVE stock rated it a Buy, with one assigning a Hold rating, resulting in a Strong Buy consensus. Their 12-month average HIVE Digital price target indicates an upside of 166.9%.
Bitdeer Technologies – Bitdeer Technologies is a Bitcoin mining company that also develops mining machines and provides infrastructure services to other cryptocurrency mining businesses. The company recently signed a 10-year agreement for a 67MW AI data center in Malaysia, with full capacity expected by Q2 2027. The addition will take Bitdeer’s secured AI data center capacity to 273.5MW, about 78% of its 350MW target.
Over the last three months, nine Wall Street analysts covering BTDR stock have rated it a Buy and one analyst rated it a Hold, resulting in a Strong Buy consensus. Their 12-month average Bitdeer price target indicates an upside of nearly 123%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
University of Michigan October Consumer Sentiment Index falls to a five-month low, with the Current Economic Conditions Indicator hitting a historic low
The University of Michigan’s Consumer Sentiment Index for October dropped to 46.3, below the market expectation of 47.6. The component reflecting current economic conditions decreased to 44.7, setting a new historical low, while the expectations component edged up to 47.3, marking its first rebound since July. Consumers’ one-year inflation expectations rose to 4.7%, and five-to-ten-year inflation expectations increased to 3.5%. According to the survey director, consumers from different political parties agree that the economic outlook has weakened compared to the beginning of the year.
WTI holds steady as traders weigh US-Iran tensions and supply risks
Japan: Bond outflows reshape global yields - Commerzbank
BUZZ - JPMorgan gives “overweight” rating to LSD-based therapies, Definium stock rises
Latest Updates, October 9th - ** Definium Therapeutics (DFTX.O) shares rose 7.4% to $36.7 ** If the rally holds, the stock is set for its biggest single-day gain since June ** JPMorgan initiated coverage of the stock with an "Overweight" rating and a target price of $84 ** The bank stated that Definium’s lead candidate drug, DT120 ODT, has the potential to transform the treatment landscape for neuropsychiatric disorders ** Based on current data, the institution considers DT120 ODT (an LSD oral formulation for the treatment of major depressive disorder and generalized anxiety disorder) to be a "de-risked asset" ** The new target price implies a 145.7% upside from the latest closing price ** "While changes in the macro environment may present potential investment risks to the sector, we believe the positives for Definium outweigh the negatives," the bank stated ** A period of "frequent landmark events" is expected ahead, including plans to submit a new drug application to the FDA in the first half of 2027 ** The bank projects that total sales of DT120 orally disintegrating tablets (ODT) will approach $5 billion by 2035 ** Including intraday volatility, the stock has more than doubled in value year-to-date (For the convenience of non-English speakers, Reuters has automated this report’s translation into several other languages. Due to possible errors in automated translation or lack of full context, Reuters does not guarantee the accuracy of the automated translation and provides it solely as a convenience to readers. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)
Crypto prices
More
